• E-4031: hERG Potassium Channel Blocker in 3D Cardiac Electro

  2026-07-25

  E-4031 enables highly selective hERG potassium channel blockade, making it indispensable for modeling proarrhythmic substrates and QT interval prolongation in advanced cardiac organoid systems. This article details robust workflows, protocol optimizations, and troubleshooting strategies leveraging APExBIO's E-4031 for reproducible, high-content cardiac electrophysiology research.

• Cyclophosphamide (SKU A2343): Reliable Cytotoxicity for Canc

  2026-07-24

  This article provides scenario-driven guidance for researchers using Cyclophosphamide (SKU A2343) in cell viability, proliferation, and cytotoxicity assays. By addressing common lab challenges—ranging from protocol optimization to vendor selection—it demonstrates how APExBIO’s Cyclophosphamide supports reproducibility and workflow confidence in oncology and immunology experiments.

• Angiotensin II in Vascular Remodeling: Protocols and Pitfall

  2026-07-24

  APExBIO’s Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) empowers cardiovascular researchers to model hypertension and aortic aneurysm formation with precision. This guide delivers actionable protocols, troubleshooting strategies, and insights from the latest reference study, ensuring reproducibility in advanced vascular smooth muscle cell hypertrophy research.

• Network Medicine Identifies Apigenin as a Promising Neuropro

  2026-07-23

  A recent network medicine study systematically identified apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one) as a potent neuroprotective flavonoid for Alzheimer's disease therapy. Integrating computational and experimental approaches, the research demonstrates apigenin's modulation of apoptosis, inflammation, and microglial polarization, offering actionable targets for neurodegeneration research.

• Hierarchical Targeting and ROS-Responsive Hydrogel for Diabe

  2026-07-23

  This study introduces a dual-targeted nanoparticle-hydrogel platform that selectively repairs mitochondrial dysfunction in M1 macrophages, disrupting the reactive oxygen species (ROS) amplification loop central to diabetic periodontitis. The approach demonstrates improved local anti-inflammatory outcomes and supports bone regeneration, marking a significant advance over conventional periodontal therapies.

• CBD Attenuates Orofacial Inflammatory Pain via Endocannabino

  2026-07-22

  This study demonstrates that cannabidiol (CBD) effectively reduces both the sensory and affective components of orofacial inflammatory pain in mice by targeting endocannabinoid, inflammatory, and serotonergic pathways. The findings provide mechanistic insights supporting CBD's translational potential for comprehensive pain management, particularly in conditions where emotional deficits are prominent.

• (R,S)-Anatabine in Alzheimer's Models: Protocols and Pitfall

  2026-07-22

  (R,S)-Anatabine enables targeted soluble Aβ peptide reduction and inflammatory pathway modulation in both in vitro and in vivo Alzheimer's models. This guide delivers actionable workflows, troubleshooting insights, and cross-study perspectives to advance neurodegeneration research with confidence.

• Beclin1 Deficiency Inhibits Ferroptosis in DOX-Induced Liver

  2026-07-21

  This study identifies Beclin1 as a critical driver of ferroptosis and autophagy in doxorubicin-induced liver injury. By demonstrating that Beclin1 deficiency or DHODH overexpression mitigates oxidative stress and hepatic damage, the research suggests new molecular targets for reducing chemotherapy-related hepatotoxicity.

• Angiotensin II in Vascular Remodeling and AAA Models

  2026-07-21

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is the gold-standard peptide for recapitulating hypertension and vascular remodeling in preclinical research. This article delivers a workflow-driven guide to maximizing reproducibility and translational insight in cardiovascular and abdominal aortic aneurysm (AAA) studies, with actionable troubleshooting and protocol enhancements.

• Refining In Vitro Metrics for Anticancer Drug Evaluation

  2026-07-20

  Schwartz's dissertation redefines how in vitro assays distinguish between proliferative arrest and cell death, demonstrating that commonly used drug response metrics are not interchangeable. This nuanced approach enables more precise assessments of multikinase inhibitors like Foretinib, ultimately improving the rigor of preclinical drug evaluation.

• Clasto-Lactacystin β-lactone: Precision Proteasome Inhibitio

  2026-07-20

  Clasto-Lactacystin β-lactone stands out as a potent, irreversible, and cell-permeable proteasome inhibitor, enabling researchers to dissect the ubiquitin-proteasome pathway with unmatched specificity. Its rapid, covalent inhibition is vital for advanced studies in cell death, cancer, and viral pathogenesis, especially when workflow reproducibility and mechanistic clarity are paramount.

• Fosinopril Sodium: Mechanism, Evidence, and Research Workflo

  2026-07-19

  Fosinopril sodium is a phosphinic acid ACE inhibitor with robust activity in hypertension research. Its unique prodrug structure, dual renal-hepatic elimination, and potent blood pressure reduction properties are backed by peer-reviewed pharmacological evidence. This article details its mechanism, experimental benchmarks, and practical workflow integration for cardiovascular disease models.

• Tobramycin in Microbiology Research: Mechanistic Insights &

  2026-07-18

  Explore the advanced scientific applications of Tobramycin, a leading aminoglycoside antibiotic, in modern microbiology research. This article uncovers mechanistic depth, protocol optimization, and unique insights for antibiotic resistance studies.

• HotStart 2X Green qPCR Master Mix: Precision in Gene Express

  2026-07-17

  HotStart™ 2X Green qPCR Master Mix accelerates real-time PCR workflows with superior specificity and reproducibility, even in challenging targets. Its hot-start Taq polymerase and SYBR Green detection enable robust gene expression and nucleic acid quantification, facilitating advanced research in cancer biomarker validation and translational studies.

• FGF4-FGFR1 Signaling Preserves Podocytes in Diabetic Kidney

  2026-07-17

  This study reveals that podocyte-derived FGF4, acting through FGFR1-AMPK-FOXO1 signaling, is vital for preventing podocyte loss and maintaining glomerular function in diabetic kidney disease (DKD). The work highlights a new therapeutic axis for DKD, advancing our understanding of podocyte protection beyond conventional angiotensin II receptor antagonist strategies.

449 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page